ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO505

Induction Immunosuppressive Therapy with One versus Two Basiliximab Dosage in Kidney Transplant Patients with Low Immunological Risk: Preliminary Report

Session Information

Category: Transplantation

  • 1702 Transplantation: Clinical and Translational


  • Aguirre Campos, Diana Angelica, Hospital General Dr. Miguel Silva, Morelia, Mexico
  • Mariscal, Luis A., Hospital General Dr. Miguel Silva, Morelia, Mexico
  • Arellano, Jesus, Hospital General Dr. Miguel Silva, Morelia, Mexico

The two basiliximab dosage is supported by phase III studies which established the optimal prescription with two 20 mg intravenous dose on day 0 and 4 of renal transplant. More recent studies have shown that one single doses(20mg) achieve adequate T cell suppression with similar clinical outcomes. There is no information about this topic on Mexican population The objective of the study is to compare one single 20mg dosage of basiliximab versus standard two dosage in patients with low immunological risk.


Single center, prospective, randomized 2:1 study that included kidney transplant patients between August 2012 and February 2016 with low immunological risk. Low immunological risk was defined as live donor with antibody reactive panel I and II less than 5%.Patients were randomized to receive one (1D) versus two basiliximab dosage (2D).Renal biopsies were indicated or by protocol at 6 months and one year after renal transplantation. Statistical analysis was performed using chi-squared test and Mann-Withney U test; the rejection-free survival curve was performed by Kaplan-Meier method. A preliminary report is presented


At this moment 33 patients have been included, 23 men (69.7%), with a median age of 25 [21-34] years old and follow-up of 498 [304-722] days. There were 20 patients in the 1D group versus 13 patients on 2D group. No differences were found between demographic and clinical baseline data in both groups; the basal function of the graft was similar in both groups (creatinine 1.12 [0.8-1.3] vs 1.1 [0.9-1.2] mg/dL and GFR 85 [67-98] vs 89 [64-98] mL / min,p=NS, 1D vs 2D group, respectively), with no difference in delayed graft function, slow graft function or maintenance calcineurin inhibitor. The graft function at the end of follow-up was similar in both groups (creatinine 1.3 [1.1-1.5] vs 1.1 [0.9-1.4] mg/dL and GFR 77 [63-86] vs 79[54-102] mL/min, p=NS, 1D and 2D group respectively). Rejection-free survival was similar in both groups (Log rank=NS)


This preliminary report suggests that there is no difference in rejection-free survival and graft function at the end of follow-up with the 20 mg dose of basiliximab compared to 40 mg in patients with renal transplantation and low immunological risk. Should confirm this results with a large number of patients